Abstract
M. Hunter is characterized by an accumulation of mucopolysaccharides in cells, blood, and connective tissue as a consequence of a deficiency of the enzyme iduronate-2-sulfatase. Unlike enzyme replacement therapy with idursulfase in children, there is limited long-term experience in adult patients with Morbus Hunter.
The case presented here describes the development of a man born in 1971 who was admitted to Hemer Lung Clinic in 2005 with severe obstructive sleep apnea, pulmonary functional impairment, and ventilatory failure (FEV 1: 0.8 L, VC: 1.0 L; pO2: 52 mmHg; pCO2: 81 mmHg, 6 MWT: 100 m). Initially, the patient received symptomatic treatment with noninvasive ventilation, which achieved a considerable improvement in pulmonary function and a normalization of blood gasses. Since February 2008, the patient received additional enzyme replacement therapy with idursulfase, which resulted in a further significant functional improvement (FEV1: 1.6; VC: 2.3 L; VO2max: 1,350 mL or 28.1 mL/kg body weight), in a normalization of prior elevated pulmonary artery pressures and also in impressive changes in the physiognomy and joint mobility. In November 2010, the polysomnography and nocturnal blood gas analysis without NIV showed only a mild obstructive sleep-related breathing disorder with no sign of hypoventilation. Therapy was changed to nocturnal CPAP therapy with a constant pressure of 6 cm H2O. Additional administration of oxygen was not required. With this therapy, the patient has been asymptomatic up to September 2011.
Adult Hunter patients also benefit from enzyme replacement therapy and, in restrictive ventilatory defects with hypoventilation, from symptomatic therapy with noninvasive ventilation.
Competing interests: None declared.
Shire provided funding for translation service. The views in the manuscript do not necessarily reflect those of Shire.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- 6-MWT:
-
Six-minute walk test
- AHI:
-
Apnea/hypopnea index
- BGA:
-
Blood gas analysis
- CPAP:
-
Continuous positive airway pressure
- DLCO:
-
Diffusing capacity of the lung for carbon monoxide
- FEV1:
-
Forced expiratory volume in 1 s
- FVC:
-
Forced vital capacity
- GAG:
-
Glycosaminoglycan
- IVS:
-
Inter ventricular septum
- MPS:
-
Mucopolysaccharidosis
- NIV:
-
Noninvasive ventilation
- P01:
-
Negative airway pressure
- PA syst.:
-
Pulmonary artery systolic pressure
- pCO2 :
-
Partial pressure of carbon dioxide
- Pimax:
-
Maximal inspiration pressure
- pO2 :
-
Partial pressure of oxygen
- TLC:
-
Total lung capacity
- VC:
-
Vital capacity
- VO2max:
-
Maximum oxygen uptake
References
Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017
Beck M (2011) Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment. Curr Pharm Biotechnol 12:861–866
Burrow TA, Leslie ND (2008) Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2:311–320
Davitt SM, Hatrick A, Sabharwal T, Pearce A, Gleeson M, Adam A (2002) Tracheobronchial stent insertions in the management of major airway obstruction in a patient with Hunter syndrome (type II mucopolysaccharidosis). Eur Radiol 12:458–462
Ginzburg AS, Onal E, Aronson RM, Schild JA, Mafee MF, Lopata M (1990) Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvement. Chest 97:1496–1498
Gross ER, Lemmens HJ (2010) Hunter syndrome in an adult: beware of tracheal stenosis. Anesth Analg 110:642–643
Jones SA, Almássy Z, Beck M et al (2009) Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 32:534–543
Kamin W (2008) Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 97:57–60
Kurihara M, Kumagai K, Goto K, Imai M, Yagishita S (1992) Severe type Hunter´s syndrome. Polysomnographic and neuropathological study. Neuropediatrics 23:248–256
Le Guern E, Couillin P, Oberlé I, Ravise N, Boue J (1990) More precise localization of the gene for Hunter syndrome. Genomics 7:358–362
Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R (2001) Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 58:127–138
Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccaridosis II (Hunter syndrome). Pediatrics 121:e377–e386
Morehead JM, Parsons DS (1993) Tracheobronchomalacia in Hunter´s syndrome. Int J Pediatr Otorhinolaryngol 26:255–261
Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473
Muenzer J, Beck M, Eng CM et al (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228–e1239
Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease, 8th edn. Mc Graw-Hill, New York, pp 3421–3452
Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25
Orliaguet O, Pépin JL, Veale D, Kelkel E, Pinel N, Lévy P (1999) Hunter´s syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J 13:1195–1197
Pérez-Calvo J, Bergua Sanclemente I, López Moreno MJ et al (2011) Early response to idursulfase in a 31-year old male patient with Hunter syndrome. Rev Clin Esp 211:e42–e45
Sasaki CT, Ruiz R, Gaito R Jr, Kirchner JA, Seshi B (1987) Hunter’s syndrome: a study in airway obstruction. Laryngoscope 97:280–285
Shapiro J, Strome M, Crocker AC (1985) Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94:458–461
Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccaridosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277
Yoskovith A, Tewfik TL, Brouillette RT, Schloss MD, Der Kaloustian VM (1998) Acute airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 44:273–278
Young ID, Harper PS (1979) Long-term complications in Hunter´s syndrome. Clin Genet 16:125–132
Young ID, Harper PS (1982) Mild form of Hunter´s syndrome: clinical delineation based on 31 cases. Arch Dis Child 57:828–836
Young ID, Harper PS (1983) The natural history of the severe form of Hunter´s syndrome: a study based on 52 cases. Dev Med Child Neurol 25:481–489
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Verena Peters.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Westhoff, M., Litterst, P. (2011). Successful Noninvasive Ventilation and Enzyme Replacement Therapy in an Adult Patient with Morbus Hunter. In: JIMD Reports - Case and Research Reports, 2012/2. JIMD Reports, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_100
Download citation
DOI: https://doi.org/10.1007/8904_2011_100
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28095-5
Online ISBN: 978-3-642-28096-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)